Who Exports Mebendazole from India — 259 Suppliers Behind a $13.7M Market
India's mebendazole export market is supplied by 259 active exporters who collectively shipped $13.7M across 2,932 shipments. KROSYL PHARMACEUTICALS PRIVATE LIMITED leads with a 19.7% market share, followed by CADILA PHARMACEUTICALS LIMITED and LINCOLN PHARMACEUTICALS LTD. The top 5 suppliers together control 54.5% of total export value, reflecting a moderately competitive market structure.
Top Mebendazole Exporters from India — Ranked by Export Value
KROSYL PHARMACEUTICALS PRIVATE LIMITED is the leading mebendazole exporter from India, holding a 19.7% share of the $13.7M market across 2,932 shipments from 259 exporters. The top 5 suppliers — KROSYL PHARMACEUTICALS PRIVATE LIMITED, CADILA PHARMACEUTICALS LIMITED, LINCOLN PHARMACEUTICALS LTD, J B CHEMICALS AND PHARMACEUTICALS LIMITED, PRASHI PHARMA PRIVATE LIMITED — collectively control 54.5% of total export value, indicating a moderately concentrated market. Individual shares are: KROSYL PHARMACEUTICALS PRIVATE LIMITED (19.7%), CADILA PHARMACEUTICALS LIMITED (19.6%), LINCOLN PHARMACEUTICALS LTD (8.5%), J B CHEMICALS AND PHARMACEUTICALS LIMITED (3.9%), PRASHI PHARMA PRIVATE LIMITED (2.9%).
Top Mebendazole Exporters from India
Ranked by export value · 259 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | KROSYL PHARMACEUTICALS PRIVATE LIMITED MEBENDAZOLE ORAL SUSPENSION USP 100MG/5MPHARMACEUTICAL PRODUCTS MEDICINES - MEBENDAZOLE SUSHARMLESS MEDICINES FOR HUMAN CONSUMPTION MEBENDAZOLE TABLET | $2.7M | 1 | 19.7% |
| 2 | CADILA PHARMACEUTICALS LIMITED MEBENDAZOLE POWDER FOR ORAL SUSPENSION 1WERMOZIM 500 DETAILS AS PER INVOICE AND PACKINGLISTMEBENDAZOLE TABLETS USP 100MG | $2.7M | 9 | 19.6% |
| 3 | LINCOLN PHARMACEUTICALS LTD MEBENDAZOLE POWDER FOR ORAL SUSPENSION 1 | $1.2M | 1 | 8.5% |
| 4 | J B CHEMICALS AND PHARMACEUTICALS LIMITED MEBENDAZOLE 100MG TABLET (ENDAL-100 TABLVERMOREX 30ML ETH EXPVERMOREX MEBENDAZOLE SUSP 30ML ETH EXP | $539.7K | 4 | 3.9% |
| 5 | PRASHI PHARMA PRIVATE LIMITED | $398.2K | 3 | 2.9% |
| 6 | BEID HEALTHCARE PRIVATE LIMITED BULK ZEROVER SUSPENSION (MEBENDAZOLE ORABULK VERGO 4% SUSPENSION 1BULK ZEROVER TABLET | $318.2K | 2 | 2.3% |
| 7 | J B CHEMICALS PHARMACEUTICALS LIMITED MEBENDAZOLE 100MG TABLET (ENDAL-100 TABLVERMOREX 30ML ETH EXPVERMOREX MEBENDAZOLE SUSP 30ML ETH EXP | $313.9K | 4 | 2.3% |
| 8 | FOURRTS (INDIA) LABORATORIES PRIVATE LIMITED MEBENDAZOLE ORAL SUSPENSION USP 100MG/5MPHARMACEUTICAL PRODUCTS MEDICINES - MEBENDAZOLE SUSMEBENDAZOLE TABLETS USP 100MG | $256.0K | 5 | 1.9% |
| 9 | CADILA PHARMACEUTICALS LTD MEBENDAZOLE POWDER FOR ORAL SUSPENSION 1WERMOZIM 500 DETAILS AS PER INVOICE AND PACKINGLISTMEBENDAZOLE TABLETS USP 100MG | $233.7K | 2 | 1.7% |
| 10 | MEDOPHARM MEBENDAZOLE TABLETS USP 100MG | $220.3K | 9 | 1.6% |
| 11 | ZIM LABORATORIES LIMITED. WERMOZIM 500 DETAILS AS PER INVOICE AND PACKINGLIST | $197.3K | 1 | 1.4% |
| 12 | RONAK EXIM PRIVATE LTD MEBENDAZOLE ORAL SUSPENSION USP 100MG/5MPHARMACEUTICAL PRODUCTS MEDICINES - MEBENDAZOLE SUSMEBENDAZOLE 100MG TAB | $188.4K | 4 | 1.4% |
| 13 | BAFNA PHARMACEUTICALS LIMITED WERMOZIM 500 DETAILS AS PER INVOICE AND PACKINGLISTMEBENDAZOLE 100MG TABLET (ENDAL-100 TABLVERMOREX 30ML ETH EXP | $181.4K | 2 | 1.3% |
| 14 | CIRON DRUGS AND PHARMACEUTICALS PRIVATE LIMITED | $166.1K | 3 | 1.2% |
| 15 | BHUMI PHARMACEUTICALS MEBENDAZOLE 100MG TABPHARMACEUTICAL PRODUCTS MEBOX TABLETSPHARMACEUTICAL PRODUCTS: MEBOX TABLETS QTY:6627X25X6'S | $158.3K | 3 | 1.2% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Mebendazole exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Cadila Pharmaceuticals Limited | Warning Letter, October 2 | Yes | Yes | Not verified | Received FDA warning letter for manufacturing practice violations at Ankleshwar |
| Lincoln Pharmaceuticals Ltd | Not Listed | Yes | Yes | Not verified | Received EU GMP certification for Khatraj facility in May 2020. |
| Fourrts (India) Laboratories Private Limited | Not Listed | Yes | No | Not verified | Approved by LMHRA through WHO-GMP desk audit. |
| Medopharm Private Limited | Not Listed | Yes | No | Not verified | Approved by LMHRA through WHO-GMP desk audit. |
| Troikaa Pharmaceuticals Ltd. | Not Listed | Yes | No | Not verified | Manufacturing facilities certified by WHO-GMP. |
| Intas Pharmaceuticals Ltd. | Warning Letter, December | Yes | Yes | Not verified | FDA inspection found data falsification and record destruction at Sanand plant. |
| Zydus Lifesciences Limited | Warning Letter, December | Yes | Yes | Not verified | FDA cited misbranding of Saroglitazar by Zydus Discovery DMCC. |
| Bhumi Pharmaceuticals | Not Listed | Yes | No | Not verified | Approved by LMHRA through WHO-GMP desk audit. |
TransData Nexus reviewed the regulatory standing of 8 leading Mebendazole exporters from India. 0 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 4 are EU GMP compliant. 3 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Mebendazole sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes over 40% of the country's bulk drug production. The city hosts numerous manufacturers specializing in Active Pharmaceutical Ingredients (APIs) and intermediates. For instance, SVK Laboratories Private Limited, established in 2007, focuses on producing high-quality bulk drugs and intermediates, adhering to Good Manufacturing Practices (GMP) and international standards. Similarly, Vasudha Pharma Chem Ltd, located in Jeedimetla, Hyderabad, is known for manufacturing bulk drugs and intermediates, leveraging the city's robust infrastructure and skilled workforce.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region is home to several leading pharmaceutical companies specializing in the production of finished dosage forms. For example, Alembic Pharmaceuticals, headquartered in Vadodara, manufactures and markets a wide range of pharmaceutical products, including formulations for therapeutic areas such as cardiology, dermatology, and infectious diseases. Additionally, Schwitz Biotech in Ahmedabad engages in formulating, manufacturing, and exporting a diverse range of pharmaceutical formulations, ensuring compliance with FDA, WHO, GMP, and ISO 9002 quality standards.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad region serves as a pivotal export gateway for India's pharmaceutical industry. Its strategic coastal location facilitates efficient international shipping, making it a hub for pharmaceutical exports. The region's well-developed infrastructure and proximity to major ports enhance its role in the global pharmaceutical supply chain.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing zone, primarily due to favorable tax incentives. This area attracts numerous pharmaceutical companies seeking cost-effective production solutions, contributing to its rapid industrial growth.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with manufacturers across different clusters to mitigate risks associated with regional disruptions.
- Leverage Regional Specializations: Source APIs from Hyderabad's bulk drug manufacturers and formulations from Ahmedabad-Vadodara's specialized companies to optimize quality and cost.
- Utilize Export Hubs: Coordinate shipments through the Mumbai-Thane-Raigad region to capitalize on its efficient export infrastructure.
- Consider Cost Advantages: Explore manufacturing partnerships in the Baddi-Nalagarh region to benefit from tax incentives and reduced production costs.
By strategically aligning sourcing and distribution with the strengths of India's pharmaceutical clusters, companies can enhance supply chain efficiency and resilience.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Mebendazole exporters from India
J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) — Torrent Pharmaceuticals to acquire controlling stake in JB Pharma
Torrent Pharmaceuticals entered into definitive agreements to acquire a controlling stake in JB Pharma from KKR, valuing JB Pharma’s equity at INR 25,689 crores. The acquisition is set to occur in phases, beginning with Torrent’s purchase of 46.39%, followed by a merger of JB Pharma into Torrent via a scheme of arrangement. - IMPACT: This acquisition may lead to strategic realignments affecting JB Pharma's Mebendazole export operations.
Impact: This acquisition may lead to strategic realignments affecting JB Pharma's Mebendazole export operations.
J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) — JB Pharma open to more acquisitions to grow branded business share
JB Pharma, controlled by KKR, is evaluating assets for acquisitions to bolster its market share in the domestic branded formulation business. CEO Nikhil Chopra emphasized that potential assets should align with existing operations and offer a payback period of seven to eight years. - IMPACT: Future acquisitions could influence JB Pharma's Mebendazole export strategies and market positioning.
Impact: Future acquisitions could influence JB Pharma's Mebendazole export strategies and market positioning.
J.B. Chemicals & Pharmaceuticals Limited (JB Pharma) — JB Pharma to acquire brands from Sanzyme
JB Pharma announced the acquisition of brands for the Indian market from Sanzyme Private Limited, a player in the probiotics and reproductive health segment. The transaction is valued at Rs. 628 crore, with the consideration payable in cash. - IMPACT: This acquisition may diversify JB Pharma's product portfolio, potentially affecting its focus on Mebendazole exports.
Impact: This acquisition may diversify JB Pharma's product portfolio, potentially affecting its focus on Mebendazole exports.
Common Questions — Mebendazole Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which mebendazole supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, KROSYL PHARMACEUTICALS PRIVATE LIMITED leads with 3 recorded shipments worth $2.7M. CADILA PHARMACEUTICALS LIMITED (111 shipments) and LINCOLN PHARMACEUTICALS LTD (22 shipments) are also established high-volume exporters.
Q How many mebendazole manufacturers are there in India?
India has 259 active mebendazole exporters with a combined export market of $13.7M across 2,932 shipments to 108 countries. The top 5 suppliers hold 54.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for mebendazole from India?
Average FOB unit price: $2.74 per unit, ranging from $0.00 to $299.22. Average shipment value: $4.7K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 259 verified Indian exporters of Mebendazole ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,932 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 108 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,932 Verified Shipments
259 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists